Johnson & Johnson Downgraded To Neutral From Overweight At JPMorgan
JPMorgan analyst Michael Weinstein downgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $150. The stock closed Friday down 81c to $139.72.
The analyst sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. He remains "fundamentally bullish" on the company, however.
Weinstein this morning upgraded both Abbott Laboratories (ABT) and Baxter International (BAX) to Overweight.
Disclaimer: TheFly.com, Inc.'s staff does NOT provide any individual investment advice or money management assistance. TheFly.com, Inc.'s employees are not brokers, dealers or registered ...
more
How did you like this article? Let us know so we can better customize your reading experience.
Comments
Leave a comment to automatically be entered into
our contest to win a free Echo Show.
